A group of scientists working out of the University of South Florida have managed to create an innovative new biomedical device that is designed to make it easier than ever for patients' blood and urine samples to be quickly and easily be analyzed by doctors right in their office.
The Mobile Enzyme Linked Immunosorbent Assay, or MELISA for short, can analyze smartphone photos to study samples, with a special smartphone app being used to carry out color analysis to determine what antibodies might be ailing patients.
Presently, it's common protocol for blood and urine samples to be sent to a separate lab. By making it possible to use smartphone data and app interfaces to produce quicker test results, the MELISA biomedical device aims to improve outcomes while reducing healthcare costs.
Image Credit: Arsenii Zhdanov
What Makes This Trend Stand Out
- Mobile Diagnostic Technology
- The MELISA biomedical device utilizes smartphone data and app interfaces to quickly analyze patient samples, showcasing the trend of mobile diagnostic technology.
- Point-of-care Testing
- By allowing doctors to analyze samples in their office, the MELISA biomedical device contributes to the trend of point-of-care testing, providing faster results and improved outcomes.
- Image Analysis in Healthcare
- The MELISA device's use of smartphone photos and color analysis demonstrates the trend of incorporating image analysis in healthcare for efficient sample evaluation.
Sectors Adopting This
- Biomedical Devices
- The MELISA device falls under the biomedical devices industry, offering potential disruptive innovation opportunities in mobile diagnostics and point-of-care technology.
- Healthcare Technology
- The MELISA device relates to the healthcare technology industry, presenting opportunities for disruptive innovations in image analysis and smartphone-based diagnostics.
- Lab Testing Services
- With the potential for decreased reliance on external labs, the MELISA device has the potential to impact the lab testing services industry, leading to new opportunities for on-site testing solutions.
